- Home
- PRLD vs JSPR Comparison
PRLD vs JSPR Comparison
Compare PRLD & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- JSPR
- Stock Information
- Founded
- PRLD 2016
- JSPR 2018
- Country
- PRLD United States
- JSPR United States
- Employees
- PRLD N/A
- JSPR N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRLD Health Care
- JSPR Health Care
- Exchange
- PRLD Nasdaq
- JSPR Nasdaq
- Market Cap
- PRLD 44.0M
- JSPR 47.6M
- IPO Year
- PRLD 2020
- JSPR N/A
- Fundamental
- Price
- PRLD $1.03
- JSPR $2.57
- Analyst Decision
- PRLD Strong Buy
- JSPR Buy
- Analyst Count
- PRLD 3
- JSPR 12
- Target Price
- PRLD $4.00
- JSPR $30.78
- AVG Volume (30 Days)
- PRLD 231.3K
- JSPR 139.0K
- Earning Date
- PRLD 11-05-2025
- JSPR 11-06-2025
- Dividend Yield
- PRLD N/A
- JSPR N/A
- EPS Growth
- PRLD N/A
- JSPR N/A
- EPS
- PRLD N/A
- JSPR N/A
- Revenue
- PRLD $7,000,000.00
- JSPR N/A
- Revenue This Year
- PRLD N/A
- JSPR N/A
- Revenue Next Year
- PRLD N/A
- JSPR N/A
- P/E Ratio
- PRLD N/A
- JSPR N/A
- Revenue Growth
- PRLD N/A
- JSPR N/A
- 52 Week Low
- PRLD $0.61
- JSPR $2.27
- 52 Week High
- PRLD $2.72
- JSPR $26.05
- Technical
- Relative Strength Index (RSI)
- PRLD 45.61
- JSPR 41.78
- Support Level
- PRLD $1.03
- JSPR $2.32
- Resistance Level
- PRLD $1.26
- JSPR $2.50
- Average True Range (ATR)
- PRLD 0.11
- JSPR 0.14
- MACD
- PRLD -0.03
- JSPR 0.00
- Stochastic Oscillator
- PRLD 10.34
- JSPR 43.62
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.